Aclaris Therapeutics, Inc.

LSE:0H8T Stock Report

Market Cap: US$141.8m

Aclaris Therapeutics Ownership

Who are the major shareholders and have insiders been buying or selling?

Recent Insider Transactions

LSE:0H8T Recent Insider Transactions by Companies or Individuals
DateValueNameEntityRoleSharesMax Price
19 Nov 24BuyUS$1,499,999Anand MehraIndividual666,666US$2.25
05 Aug 24BuyUS$472,757BML Capital Management, LLCCompany373,569US$1.29
31 Jul 24BuyUS$359,010BML Capital Management, LLCCompany273,730US$1.33
22 Jul 24BuyUS$201,808BML Capital Management, LLCCompany154,722US$1.33
05 Jul 24BuyUS$405,894BML Capital Management, LLCCompany352,397US$1.16
01 Jul 24BuyUS$1,742,075BML Capital Management, LLCCompany1,543,434US$1.15
18 Jun 24BuyUS$628,206BML Capital Management, LLCCompany545,000US$1.17
13 Jun 24BuyUS$1,781,897BML Capital Management, LLCCompany1,611,200US$1.15

Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.

Ownership Breakdown

What is the ownership structure of 0H8T?
Owner TypeNumber of SharesOwnership Percentage
Individual Insiders2,885,8302.67%
VC/PE Firms8,888,8888.21%
General Public9,962,2489.2%
Hedge Funds29,420,44227.2%
Institutions57,123,83152.8%

Dilution of Shares: Shareholders have been substantially diluted in the past year, with total shares outstanding growing by 51.9%.

Top Shareholders

Top 25 shareholders own 76.38% of the company
OwnershipNameSharesCurrent ValueChange %Portfolio %
13.2%
BML Capital Management, LLC
14,250,000US$18.7m0%15.15%
8.89%
Adage Capital Management, L.P.
9,627,304US$12.6m0%0.02%
8.21%
Vivo Capital, LLC
8,888,888US$11.6m0%0.97%
5.12%
Millennium Management LLC
5,543,138US$7.3m34.1%0.01%
4.66%
Rock Springs Capital Management LP
5,046,309US$6.6m-18.7%0.38%
4.59%
The Vanguard Group, Inc.
4,970,254US$6.5m14.9%no data
4.31%
RA Capital Management, L.P.
4,666,667US$6.1m0%0.09%
3.73%
Decheng Capital LLC
4,041,736US$5.3m78.3%1.37%
2.72%
D. E. Shaw & Co., L.P.
2,944,512US$3.9m-10.6%no data
2.23%
Morgan Stanley, Investment Banking and Brokerage Investments
2,413,153US$3.2m126%no data
2.14%
Marshall Wace LLP
2,312,926US$3.0m-12.2%no data
2.05%
Logos Global Management, L.P.
2,222,222US$2.9m0%0.5%
1.61%
Acadian Asset Management LLC
1,744,147US$2.3m0%0.01%
1.37%
Neal Walker
1,479,824US$1.9m0.88%no data
1.32%
The Bollard Group, LLC
1,424,176US$1.9m0%0.05%
1.28%
Susquehanna International Group, LLP, Asset Management Arm
1,381,741US$1.8m1,650%no data
1.26%
BlackRock, Inc.
1,360,728US$1.8m8.21%no data
1.25%
Qube Research & Technologies Ltd
1,350,820US$1.8m120%no data
1.09%
Geode Capital Management, LLC
1,182,737US$1.5m49.8%no data
1.04%
Citadel Advisors LLC
1,122,081US$1.5m1,930%no data
0.93%
Aldebaran Capital, LLC
1,007,958US$1.3m-0.88%1.27%
0.89%
PEH Wertpapier AG
963,544US$1.3m0%0.08%
0.88%
Renaissance Technologies LLC
951,394US$1.2m11.9%no data
0.85%
Deutsche Asset & Wealth Management
923,313US$1.2m0%no data
0.82%
Monashee Investment Management, LLC
888,888US$1.2m0%0.13%

Company Analysis and Financial Data Status

DataLast Updated (UTC time)
Company Analysis2025/05/19 11:44
End of Day Share Price 2025/05/16 00:00
Earnings2025/03/31
Annual Earnings2024/12/31

Data Sources

The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.

PackageDataTimeframeExample US Source *
Company Financials10 years
  • Income statement
  • Cash flow statement
  • Balance sheet
Analyst Consensus Estimates+3 years
  • Forecast financials
  • Analyst price targets
Market Prices30 years
  • Stock prices
  • Dividends, Splits and Actions
Ownership10 years
  • Top shareholders
  • Insider trading
Management10 years
  • Leadership team
  • Board of directors
Key Developments10 years
  • Company announcements

* Example for US securities, for non-US equivalent regulatory forms and sources are used.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.

Analysis Model and Snowflake

Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.

Learn about the world class team who designed and built the Simply Wall St analysis model.

Industry and Sector Metrics

Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.

Analyst Sources

Aclaris Therapeutics, Inc. is covered by 15 analysts. 6 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.

AnalystInstitution
Louise ChenCantor Fitzgerald & Co.
Prakhar AgrawalCantor Fitzgerald & Co.
Donald EllisCitizens JMP Securities, LLC